Michael Barbella, Managing Editor03.31.22
Perineologic has undergone a top regime change.
The company promoted President Matthew J. Allaway, D.O., to CEO and appointed 35-year medical device industry veteran Jim Fortune as president. Fortune will lead Perineologic's business strategy and operations management.
“We are at a significant stage of growth at the company and attracting top talent and further strengthening our leadership team is essential to our success,” said Allaway. “We are pleased to have Jim join our team as his broad industry experience, including supporting the commercialization, manufacturing and ongoing sales strategies of new medical devices, will be valuable as we continue our efforts to expand market adoption of PrecisionPoint. I look forward to working with him closely in my new role.”
Before joining Perineologic, Fortune was chief operating officer (COO) at Ocular Therapeutix Inc. where he led internal operations of this startup through later stages as a public company with an early-stage, PMA-approved commercial device and several Phase 2 and Phase 3 drug delivery products. Before that, he served as COO at AccessClosure (acquired by Cardinal Health Inc.) and COO at Incept LLC, an intellectual property holding partnership that creates and operates medical device startup companies. At Incept, Fortune provided operational strategy, organizational direction, and leadership and tactical support to companies including Augmenix Inc. and Claret Medical Inc.—both of which were acquired by Boston Scientific Corporation—HotSpur Technologies Inc. (acquired by Teleflex Incorporated), Maya Medical (acquired by Covidien plc) and Ostial Corporation. Before that, he was COO and chief financial officer at Confluent Surgical (acquired by Integra LifeSciences Holdings Corporation). Earlier in his career, Fortune was a general manager at DePuy Synthes, the Orthopaedics Company of Johnson & Johnson.
Fortune earned his bachelor’s degree in mechanical engineering from Rensselaer Polytechnic Institute. He also currently works as an operations management consultant at Fortune Consulting LLC.
“The overall goal for anyone in the medical device industry is to make a meaningful difference in the lives of patients and improve quality of care. I was attracted to Perineologic because of the significant potential that the PrecisionPoint Transperineal Access System has to positively transform the standard of care in prostate biopsy by providing a more streamlined procedure process for clinicians and important benefits for patients. I am excited to join this team and support widespread adoption of this biopsy technique,” said Fortune.
Dr. Allaway is the founder of Perineologic and has been a practicing urologist and managing partner at Urology Associates in Cumberland, Md., for about 20 years, with a focus on prostate cancer and female urology.
Perineologic, a subsidiary of Corbin Clinical Resources Inc., is a private, self-funded medical device company developing and delivering technology to improve the safety, precision, and efficiency of urologic healthcare options. The company is initially focused on finding a new approach to cancer detection. Its first product, the PrecisionPoint Transperineal Access System for prostate cancer biopsy, received U.S. Food and Drug Administration clearance in 2016 and is available in 13 other countries.
The company promoted President Matthew J. Allaway, D.O., to CEO and appointed 35-year medical device industry veteran Jim Fortune as president. Fortune will lead Perineologic's business strategy and operations management.
“We are at a significant stage of growth at the company and attracting top talent and further strengthening our leadership team is essential to our success,” said Allaway. “We are pleased to have Jim join our team as his broad industry experience, including supporting the commercialization, manufacturing and ongoing sales strategies of new medical devices, will be valuable as we continue our efforts to expand market adoption of PrecisionPoint. I look forward to working with him closely in my new role.”
Before joining Perineologic, Fortune was chief operating officer (COO) at Ocular Therapeutix Inc. where he led internal operations of this startup through later stages as a public company with an early-stage, PMA-approved commercial device and several Phase 2 and Phase 3 drug delivery products. Before that, he served as COO at AccessClosure (acquired by Cardinal Health Inc.) and COO at Incept LLC, an intellectual property holding partnership that creates and operates medical device startup companies. At Incept, Fortune provided operational strategy, organizational direction, and leadership and tactical support to companies including Augmenix Inc. and Claret Medical Inc.—both of which were acquired by Boston Scientific Corporation—HotSpur Technologies Inc. (acquired by Teleflex Incorporated), Maya Medical (acquired by Covidien plc) and Ostial Corporation. Before that, he was COO and chief financial officer at Confluent Surgical (acquired by Integra LifeSciences Holdings Corporation). Earlier in his career, Fortune was a general manager at DePuy Synthes, the Orthopaedics Company of Johnson & Johnson.
Fortune earned his bachelor’s degree in mechanical engineering from Rensselaer Polytechnic Institute. He also currently works as an operations management consultant at Fortune Consulting LLC.
“The overall goal for anyone in the medical device industry is to make a meaningful difference in the lives of patients and improve quality of care. I was attracted to Perineologic because of the significant potential that the PrecisionPoint Transperineal Access System has to positively transform the standard of care in prostate biopsy by providing a more streamlined procedure process for clinicians and important benefits for patients. I am excited to join this team and support widespread adoption of this biopsy technique,” said Fortune.
Dr. Allaway is the founder of Perineologic and has been a practicing urologist and managing partner at Urology Associates in Cumberland, Md., for about 20 years, with a focus on prostate cancer and female urology.
Perineologic, a subsidiary of Corbin Clinical Resources Inc., is a private, self-funded medical device company developing and delivering technology to improve the safety, precision, and efficiency of urologic healthcare options. The company is initially focused on finding a new approach to cancer detection. Its first product, the PrecisionPoint Transperineal Access System for prostate cancer biopsy, received U.S. Food and Drug Administration clearance in 2016 and is available in 13 other countries.